小分子靶向药物和生物制剂治疗斑秃的研究进展

doi:10.35541/cjd.20200563

Abstract

Abstract: 【Abstract】 Traditional therapies for alopecia areata, especially moderate to severe alopecia areata and special types of alopecia areata, remain unsatisfactory. Compared with traditional therapies, small-molecule targeted drugs and biological agents have advantages of more rapid and marked efficacy, however, some patients may experience adverse reactions such as infections during treatment or relapses after drug withdrawal. Thus, their efficacy and safety still need to be further evaluated. This review summarizes research progress in small-molecule targeted drugs and biological agents in the treatment of alopecia areata.

Key words: Alopecia areata, Molecular targeted therapy, Biological therapy

Ding Yuwei, Qiao Jianjun, Fang Hong. Small-molecule targeted drugs and biological agents for alopecia areata[J]. Chinese Journal of Dermatology, 2022, 55(12): 1118-1121.doi:10.35541/cjd.20200563

References ［41］

［1］	中华医学会皮肤性病学分会毛发学组. 中国斑秃诊疗指南（2019）［J］. 临床皮肤科杂志, 2020,49（2）:69⁃72. doi: 10.16761/ j.cnki.1000⁃4963.2020.02.002.
［2］	Shreberk⁃Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review［J］. J Am Acad Dermatol, 2017,76（4）:745⁃753.e19. doi: 10.1016/j.jaad.2016.12. 004.
［3］	Pratt CH, King LE Jr, Messenger AG, et al. Alopecia areata［J］. Nat Rev Dis Primers, 2017,3:17011. doi: 10.1038/nrdp.2017.11.
［4］	Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata［J］. Drug Des Devel Ther, 2018,12:2323⁃2335. doi: 10.2147/DDDT.S172638.
［5］	Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis［J］. J Invest Dermatol, 2014,134（12）:2988⁃2990. doi: 10.1038/jid.2014.260.
［6］	Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata［J］. JCI Insight, 2016,1（15）:e89776. doi: 10.1172/jci.insight.89776.
［7］	Guo L, Feng S, Sun B, et al. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2020,34（1）:192⁃201. doi: 10.1111/jdv.15937.
［8］	Mackay⁃Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate⁃to⁃severe alopecia areata［J］. JCI Insight, 2016,1（15）:e89790. doi: 10.1172/ jci.insight.89790.
［9］	Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib［J］. EBioMedicine, 2015,2（4）:351⁃355. doi: 10.1016/j.ebiom.2015. 02.015.
［10］	Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib［J］. JAAD Case Rep, 2019,5（10）:892⁃894. doi: 10.1016/j.jdcr.2019.07.005.
［11］	Lee JS, Huh CH, Kwon O, et al. Nail involvement in patients with moderate⁃to⁃severe alopecia areata treated with oral tofacitinib［J］. J Dermatolog Treat, 2018,29（8）:819⁃822. doi: 10.1080/09546634.2018.1466024.
［12］	Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children［J］. J Am Acad Dermatol, 2019,80（2）:568⁃570. doi: 10.1016/j.jaad.2018.08.041.
［13］	Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata［J］. J Am Acad Dermatol, 2019,80（4）:1164⁃1166. doi: 10.1016/j.jaad.2018.12.041.
［14］	Peterson DM, Vesely MD. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient［J］. JAAD Case Rep, 2020,6（4）:257⁃259. doi: 10.1016/j.jdcr.2020.02.007.
［15］	Jabbari A, Sansaricq F, Cerise J, et al. An open⁃label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch⁃type alopecia areata, totalis, and universalis［J］. J Invest Dermatol, 2018,138（7）:1539⁃1545. doi: 10.1016/j.jid. 2018.01.032.
［16］	Chen YY, Lin SY, Chen YC, et al. Low⁃dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost⁃saving regimen［J］. Eur J Dermatol, 2019,29（6）:667⁃669. doi: 10.1684/ejd.2019.3668.
［17］	Gilhar A, Keren A, Paus R. JAK inhibitors and alopecia areata［J］. Lancet, 2019,393（10169）:318⁃319. doi: 10.1016/S0140⁃6736（18）32987⁃8.
［18］	Shivanna CB, Shenoy C, Priya RA. Tofacitinib （selective janus kinase inhibitor 1 and 3）: a promising therapy for the treatment of alopecia areata: a case report of six patients［J］. Int J Trichology, 2018,10（3）:103⁃107. doi: 10.4103/ijt.ijt_21_18.
［19］	Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis［J］. JAMA Dermatol, 2016,152（4）:490⁃491. doi: 10.1001/jamadermatol.2015.4445.
［20］	Craiglow BG. Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes［J］. JAAD Case Rep, 2018,4（10）:988⁃989. doi: 10.1016/j.jdcr.2018.07.018.
［21］	Bokhari L, Sinclair R. Treatment of alopecia universalis with topical Janus kinase inhibitors ⁃ a double blind, placebo, and active controlled pilot study［J］. Int J Dermatol, 2018,57（12）:1464⁃1470. doi: 10.1111/ijd.14192.
［22］	Deeb M, Beach RA. A case of topical ruxolitinib treatment failure in alopecia areata［J］. J Cutan Med Surg, 2017,21（6）:562⁃563. doi: 10.1177/1203475417716363.
［23］	Keren A, Shemer A, Ullmann Y, et al. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo［J］. J Dermatol Sci, 2015,77（1）:74⁃76. doi: 10.1016/j.jdermsci.2014.11.009.
［24］	Magdaleno⁃Tapial J, Valenzuela⁃Oñate C, Sánchez⁃Carazo JL, et al. Improvement of alopecia areata with apremilast［J］. Australas J Dermatol, 2019,60（2）:144⁃145. doi: 10.1111/ajd.12934
［25］	Liu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata［J］. J Am Acad Dermatol, 2017,77（4）:773⁃774. doi: 10.1016/j.jaad.2017.05.034.
［26］	Mikhaylov D, Pavel A, Yao C, et al. A randomized placebo⁃controlled single⁃center pilot study of the safety and efficacy of apremilast in subjects with moderate⁃to⁃severe alopecia areata［J］. Arch Dermatol Res, 2019,311（1）:29⁃36. doi: 10.1007/s00403⁃018⁃1876⁃y.
［27］	Weber B, Radakovic S, Tanew A. Apremilast for extensive and treatment⁃resistant alopecia areata: a retrospective analysis of five patients［J］. Eur J Dermatol, 2020,30（2）:165⁃168. doi: 10.1684/ejd.2020. 3749.
［28］	Wang TT, Yang J, Zhang Y, et al. IL⁃2 and IL⁃15 blockade by BNZ⁃1, an inhibitor of selective γ⁃chain cytokines, decreases leukemic T⁃cell viability［J］. Leukemia, 2019,33（5）:1243⁃1255. doi: 10.1038/s41375⁃018⁃0290⁃y.
［29］	Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition［J］. Nat Med, 2014,20（9）:1043⁃1049. doi: 10.1038/nm.3645.
［30］	Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. N Engl J Med, 2014,371（2）:130⁃139. doi: 10.1056/NEJMoa1314768.
［31］	Renert⁃Yuval Y, Guttman⁃Yassky E. A novel therapeutic paradigm for patients with extensive alopecia areata［J］. Expert Opin Biol Ther, 2016,16（8）:1005⁃1014. doi: 10.1080/14712598. 2016.1188076.
［32］	Penzi LR, Yasuda M, Manatis⁃Lornell A, et al. Hair regrowth in a patient with long⁃standing alopecia totalis and atopic dermatitis treated with dupilumab［J］. JAMA Dermatol, 2018,154（11）:1358⁃1360. doi: 10.1001/jamadermatol.2018.2976.
［34］	Marks DH, Mesinkovska N, Senna MM. Cause or cure? Review of dupilumab and alopecia areata［J］. J Am Acad Dermatol, 2019. doi: 10.1016/j.jaad.2019.06.010.
［35］	Renert⁃Yuval Y, Guttman⁃Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm［J］. Adv Ther, 2017,34（7）:1594⁃1609. doi: 10.1007/s12325⁃017⁃0542⁃7.
［36］	Kasumagic⁃Halilovic E, Prohic A, Cavaljuga S. Tumor necrosis factor⁃alpha in patients with alopecia areata［J］. Indian J Dermatol, 2011,56（5）:494⁃496. doi: 10.4103/0019⁃5154.87124.
［37］	Özkur E, Altunay İK, Leblebici C, et al. Adalimumab⁃induced scalp psoriasis with severe alopecia［J］. Dermatol Ther, 2019,32（5）:e13033. doi: 10.1111/dth.13033.
［38］	Béné J, Moulis G, Auffret M, et al. Alopecia induced by tumour necrosis factor⁃alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmaco⁃vigilancedatabase［J］. Rheumatology （Oxford）, 2014,53（8）:1465⁃1469. doi: 10.1093/rheumatology/keu145.
［39］	Tauber M, Buche S, Reygagne P, et al. Alopecia areata occurring during anti⁃TNF therapy: a national multicenter prospective study［J］. J Am Acad Dermatol, 2014,70（6）:1146⁃1149. doi: 10.1016/j.jaad.2014.03.005.
［40］	Gorcey L, Gordon Spratt EA, Leger MC. Alopecia universalis successfully treated with adalimumab［J］. JAMA Dermatol, 2014,150（12）:1341⁃1344. doi: 10.1001/jamadermatol.2014.1544.
［41］	Blair HA, Deeks ED. Abatacept: a review in rheumatoid arthritis［J］. Drugs, 2017,77（11）:1221⁃1233. doi: 10.1007/s40265⁃017⁃0775⁃4.

[1]	Ding Yuxin, Lyu Zhongfa. Stem cell therapy for alopecia areata [J]. Chinese Journal of Dermatology, 2022, 55(9): 835-838.
[2]	Zhao Peng, Qin Xiaowei, Qin Junxia, Liang Lili, Zhang Xinzhong, Gao Jie. Regulatory effect of interleukin-18 on natural killer cell activity in patients with alopecia areata [J]. Chinese Journal of Dermatology, 2022, 55(9): 778-783.
[3]	Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 55(7): 603-609.
[4]	Zhao Peng, Qin Xiaowei, Qin Junxia, Liang Lili, Zhang Xinzhong, Gao Jie. Expression of peripheral interleukin-35 and its modulatory effect on regulatory T cell functions in patients with alopecia areata [J]. Chinese Journal of Dermatology, 2022, 55(3): 224-230.
[5]	Xingqi Zhang. T helper type 2 immune response in alopecia areata [J]. Chinese Journal of Dermatology, 2022, 55(11): 1013-1018.
[6]	Wang Guanyu, Wang Yimeng, Li Weiwei, Zhang Chunlei. Novel non-chemotherapeutic treatment options for relapsed/refractory cutaneous T-cell lymphomas [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210850-e20210850.
[7]	Ji Xiang, Wang Daguang. Biotherapy for cutaneous squamous cell carcinoma [J]. Chinese Journal of Dermatology, 2022, 0(1): 20220172-e20220172.
[8]	Cao Meng, Hong Anlan, Wang Yan, Fang Fang. Clinical progress in pediatric melanoma [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210158-e20210158.
[9]	Wang Yuqian, Qiao Jianjun, Fang Hong. Comparison of the latest Chinese and international guidelines/consensus on diagnosis and treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210184-e20210184.
[10]	Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210248-e20210248.
[11]	Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210442-e20210442.
[12]	Bai Lu, Chu Yan, Liu Yuanyuan, Zhu Caiyong. Treatment of chronic hand eczema [J]. Chinese Journal of Dermatology, 2022, 0(1): 20220028-e20220028.
[13]	Gao Yan, Wang Peng, Kang Xiaojing. Treatment of Kaposi′s sarcoma [J]. Chinese Journal of Dermatology, 2021, 0(1): 20210303-e20210303.
[14]	Gao Tianwen, Guo Weinan. Research progress in and new treatment strategies for melanoma in China [J]. Chinese Journal of Dermatology, 2021, 54(1): 27-32.
[15]	Yu Lijuan, Lyu Zhongfa. JAK inhibitors for the treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2019, 52(5): 343-346.

Small-molecule targeted drugs and biological agents for alopecia areata

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［41］

Related Articles 15

Metrics

Comments

Recommended 10